134 related articles for article (PubMed ID: 38236008)
21. Performance of HPV testing, Pap smear and VIA in women attending cervical cancer screening in Kilimanjaro region, Northern Tanzania: a cross-sectional study nested in a cohort.
Mremi A; Mchome B; Mlay J; Schledermann D; Blaakær J; Rasch V
BMJ Open; 2022 Oct; 12(10):e064321. PubMed ID: 36316070
[TBL] [Abstract][Full Text] [Related]
22. Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial.
Elfström KM; Eklund C; Lamin H; Öhman D; Hortlund M; Elfgren K; Sundström K; Dillner J
PLoS Med; 2021 Aug; 18(8):e1003748. PubMed ID: 34424907
[TBL] [Abstract][Full Text] [Related]
23. New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors.
Syrjänen K
Eur J Gynaecol Oncol; 2008; 29(3):205-21. PubMed ID: 18592782
[TBL] [Abstract][Full Text] [Related]
24. Triage of Women Testing Positive With the careHPV Test on Self-Collected Vaginal Samples for Cervical Cancer Screening in a Low-Resource Setting.
Poli UR; Gowrishankar S; Swain M; Jeronimo J
J Glob Oncol; 2018 Sep; 4():1-7. PubMed ID: 30241206
[TBL] [Abstract][Full Text] [Related]
25. Experience of Combined Liquid Based Cervical Cytology and High-Risk HPV mRNA for Cervical Cancer Screening in Thammasat University Hospital.
Muangto T; Chanthasenanont A; Lertvutivivat S; Nanthakomon T; Pongrojpaw D; Bhamarapravatana K; Suwannarurk K
Asian Pac J Cancer Prev; 2016; 17(9):4409-4413. PubMed ID: 27797253
[TBL] [Abstract][Full Text] [Related]
26. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.
Arbyn M; Verdoodt F; Snijders PJ; Verhoef VM; Suonio E; Dillner L; Minozzi S; Bellisario C; Banzi R; Zhao FH; Hillemanns P; Anttila A
Lancet Oncol; 2014 Feb; 15(2):172-83. PubMed ID: 24433684
[TBL] [Abstract][Full Text] [Related]
27. [Epidemiology and diagnosis of cervical intraepithelial neoplasia--is the present concept of screening and diagnosis still current?].
Hillemanns P; Thaler C; Kimmig R
Gynakol Geburtshilfliche Rundsch; 1997; 37(4):179-90. PubMed ID: 9609926
[TBL] [Abstract][Full Text] [Related]
28. A low-cost, paper-based hybrid capture assay to detect high-risk HPV DNA for cervical cancer screening in low-resource settings.
Smith CA; Chang MM; Kundrod KA; Novak EN; Parra SG; López L; Mavume C; Lorenzoni C; Maza M; Salcedo MP; Carns JL; Baker E; Montealegre J; Scheurer M; Castle PE; Schmeler KM; Richards-Kortum RR
Lab Chip; 2023 Jan; 23(3):451-465. PubMed ID: 36562325
[TBL] [Abstract][Full Text] [Related]
29. Comparative assessment of test characteristics of cervical cancer screening methods for implementation in low-resource settings.
Asgary R; Beideck E; Naderi R
Prev Med; 2022 Jan; 154():106883. PubMed ID: 34785209
[TBL] [Abstract][Full Text] [Related]
30. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
[TBL] [Abstract][Full Text] [Related]
31. Recall Efforts Successfully Increase Follow-Up for Cervical Cancer Screening Among Women With Human Papillomavirus in Honduras.
Thomson KA; Sandoval M; Bain C; Holme F; Bansil P; Figueroa J; de Sanjosé S
Glob Health Sci Pract; 2020 Jun; 8(2):290-299. PubMed ID: 32606095
[TBL] [Abstract][Full Text] [Related]
32. High risk HPV infection prevalence and associated cofactors: a population-based study in female ISSSTE beneficiaries attending the HPV screening and early detection of cervical cancer program.
Torres-Poveda K; Ruiz-Fraga I; Madrid-Marina V; Chavez M; Richardson V
BMC Cancer; 2019 Dec; 19(1):1205. PubMed ID: 31823749
[TBL] [Abstract][Full Text] [Related]
33. [Human papillomavirus associated cervix uteri morbidity in Hungary: epidemiology and correlation with the HPV types and the simultaneous cytological diagnosis].
Szentirmay Z; Veleczki Z; Kásler M
Orv Hetil; 2017 Aug; 158(31):1213-1221. PubMed ID: 28758434
[TBL] [Abstract][Full Text] [Related]
34. A comparison of ThinPrep against four non-volatile transport media for HPV testing at or near the point of care.
Badman SG; Vallely AJ; Pardo C; Mhango LP; Cornall AM; Kaldor JK; Whiley D
Pathology; 2021 Feb; 53(2):264-266. PubMed ID: 33358758
[TBL] [Abstract][Full Text] [Related]
35. Primary HPV-based cervical cancer screening in Europe: implementation status, challenges, and future plans.
Maver PJ; Poljak M
Clin Microbiol Infect; 2020 May; 26(5):579-583. PubMed ID: 31539637
[TBL] [Abstract][Full Text] [Related]
36. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
Tiews S; Steinberg W; Schneider W; Hanrath C
J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
[TBL] [Abstract][Full Text] [Related]
37. Cervical screening in HPV-vaccinated populations.
Canfell K
Climacteric; 2018 Jun; 21(3):227-234. PubMed ID: 29565690
[TBL] [Abstract][Full Text] [Related]
38. Validation of EUROArray HPV test using the VALGENT framework.
Viti J; Poljak M; Oštrbenk A; Bhatia R; Alcañiz Boada E; Cornall AM; Cuschieri K; Garland S; Xu L; Arbyn M
J Clin Virol; 2018 Nov; 108():38-42. PubMed ID: 30223253
[TBL] [Abstract][Full Text] [Related]
39. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.
Woodman CB; Collins S; Winter H; Bailey A; Ellis J; Prior P; Yates M; Rollason TP; Young LS
Lancet; 2001 Jun; 357(9271):1831-6. PubMed ID: 11410191
[TBL] [Abstract][Full Text] [Related]
40. Clinical Validation of Anyplex II HPV HR Detection Test for Cervical Cancer Screening in Korea.
Jung S; Lee B; Lee KN; Kim Y; Oh EJ
Arch Pathol Lab Med; 2016 Mar; 140(3):276-80. PubMed ID: 26927723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
